BBIO

74.45

0.26% 0.19

Handel nachbörslich: 74.45

Bridgebio Pharma Inc (BBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BBIO? Forum Prognose

Schlusskurs vom Vortag:

$74.26

Offen:

$74.765

24-Stunden-Volumen:

2.25M

Relative Volume:

0.82

Marktkapitalisierung:

$14.43B

Einnahmen:

$502.08M

Nettoeinkommen (Verlust:

$-732.94M

KGV:

-19.67

EPS:

-3.7842

Netto-Cashflow:

$-455.50M

1W Leistung:

+3.97%

1M Leistung:

+11.99%

6M Leistung:

+39.21%

1J Leistung:

+125.47%

1-Tages-Spanne:

$73.19

$75.67

1-Wochen-Bereich:

$68.83

$75.67

52-Wochen-Spanne:

$28.32

$84.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Firmenname

Bridgebio Pharma Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (621)

Telefon

(650) 391-9740

Adresse

3160 PORTER DR., PALO ALTO, CA

Mitarbeiter

839

Twitter

Nächster Verdiensttermin

2026-02-24

Neueste SEC-Einreichungen

BBIO's Discussions on Twitter

Compare BBIO vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BBIO Bridgebio Pharma Inc	74.45	14.40B	502.08M	-732.94M	-455.50M	-3.7842
VRTX Vertex Pharmaceuticals Inc	447.26	113.44B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	777.25	81.68B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	743.12	45.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	328.73	43.88B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	164.86	35.25B	606.42M	-1.28B	-997.58M	-6.403

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-10	Eingeleitet	William Blair	Outperform
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-06	Eingeleitet	Morgan Stanley	Overweight
2025-12-11	Eingeleitet	Bernstein	Outperform
2025-07-30	Fortgesetzt	Raymond James	Outperform
2025-07-21	Eingeleitet	Truist	Buy
2025-07-14	Eingeleitet	Jefferies	Buy
2025-07-09	Hochstufung	Oppenheimer	Perform → Outperform
2025-06-17	Eingeleitet	Wolfe Research	Outperform
2025-03-31	Eingeleitet	Redburn Atlantic	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-10-03	Eingeleitet	Oppenheimer	Perform
2024-09-04	Eingeleitet	Piper Sandler	Overweight
2024-03-21	Fortgesetzt	Raymond James	Outperform
2024-01-31	Eingeleitet	BMO Capital Markets	Market Perform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-11-07	Eingeleitet	Citigroup	Buy
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-07-18	Herabstufung	Jefferies	Buy → Hold
2023-04-19	Eingeleitet	Evercore ISI	Outperform
2023-02-06	Eingeleitet	Cowen	Outperform
2021-12-27	Bestätigt	Mizuho	Buy
2021-12-27	Bestätigt	SVB Leerink	Outperform
2021-09-10	Hochstufung	BofA Securities	Neutral → Buy
2021-05-21	Eingeleitet	UBS	Buy
2021-03-22	Bestätigt	Goldman	Buy
2021-02-22	Fortgesetzt	JP Morgan	Overweight
2021-02-09	Fortgesetzt	Goldman	Buy
2021-01-11	Bestätigt	H.C. Wainwright	Buy
2020-12-10	Bestätigt	H.C. Wainwright	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Neutral
2020-05-19	Eingeleitet	BTIG Research	Buy
2020-04-13	Eingeleitet	H.C. Wainwright	Buy
2020-02-19	Eingeleitet	Mizuho	Buy
2019-07-26	Eingeleitet	Raymond James	Outperform
2019-07-22	Eingeleitet	BMO Capital Markets	Outperform
2019-07-22	Eingeleitet	Goldman	Buy
2019-07-22	Eingeleitet	JP Morgan	Overweight
2019-07-22	Eingeleitet	Jefferies	Buy
2019-07-22	Eingeleitet	Piper Jaffray	Overweight
2019-07-22	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

10:20 AM

Analysts Offer Insights on Healthcare Companies: Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO) - The Globe and Mail

10:20 AM

05:55 AM

Bond Watch: Is BridgeBio Pharma Inc stock a value trapEarnings Trend Report & Step-by-Step Swing Trade Plans - baoquankhu1.vn

05:55 AM

03:10 AM

Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - marketbeat.com

03:10 AM

02:40 AM

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

02:40 AM

12:43 PM

Sentiment Review: Will BridgeBio Pharma Inc benefit from green energy policies2026 Biggest Moves & Low Volatility Stock Recommendations - baoquankhu1.vn

12:43 PM

Mar 31, 2026

Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why - Insider Monkey

Mar 31, 2026

H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo

Mar 31, 2026

Bridgebio asks FDA to approve potential 1st treatment for LGMD2i - musculardystrophynews.com

Mar 31, 2026

Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111 - Moomoo

Mar 31, 2026

BridgeBio's rare-disease pipeline sparks growth buzz - MSN

Mar 31, 2026

INVESCO Small Cap Equity Fund's BridgeBio Pharma Inc(BBIO) Holding History - GuruFocus

Mar 31, 2026

Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO - marketbeat.com

Mar 31, 2026

BridgeBio submits NDA for oral BBP-418 to treat LGMD2I/R9 - Investing.com Australia

Mar 31, 2026

BridgeBio Submits NDA for BBP-418 in LGMD2I/R9, Potentially the First Approved Therapy for Any Form of Limb-Girdle Muscular Dystrophy - Neurology Live

Mar 31, 2026

Mar 30, 2026

BridgeBio Files NDA for LGMD2I/R9 Oral Therapy - TipRanks

Mar 30, 2026

BridgeBio (BBIO) Shares Promising Long-Term Acoramidis Data at A - GuruFocus

Mar 30, 2026

BridgeBio (BBIO) Submits Application for New Muscular Dystrophy Treatment - GuruFocus

Mar 30, 2026

BridgeBio (NASDAQ: BBIO) files NDA for first potential LGMD2I/R9 treatment - stocktitan.net

Mar 30, 2026

BridgeBio reports sustained mortality benefits for acoramidis at 54 months By Investing.com - Investing.com Canada

Mar 30, 2026

BridgeBio Pharma Announces Sustained Clinical Benefits of Acoramidis in Long-Term ATTRibute-CM Trial - Quiver Quantitative

Mar 30, 2026

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 - GlobeNewswire Inc.

Mar 30, 2026

Jefferies reiterates Buy on BridgeBio Pharma stock, $100 target By Investing.com - Investing.com Canada

Mar 30, 2026

BridgeBio submits NDA to FDA for BBP-418 for individuals living with LGMD2I/R9 - marketscreener.com

Mar 30, 2026

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - manilatimes.net

Mar 30, 2026

BridgeBio Pharma stock drops 3.97% as NDA filed with FDA for BBP-418 therapy - Traders Union

Mar 30, 2026

5 High Growth Healthcare Stocks to Buy Now - Insider Monkey

Mar 30, 2026

Mar 29, 2026

BridgeBio Pharma stock price forecast: mixed signals as BBIO retreats 3.97% toward key support - Traders Union

Mar 29, 2026

Mar 28, 2026

Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? - Yahoo Finance

Mar 28, 2026

BridgeBio Pharma (MIL:1BBIO) PB Ratio : (As of Mar. 28, 2026) - GuruFocus

Mar 28, 2026

(BBIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Mar 28, 2026

Mar 27, 2026

Phase III wins lift shares of Compass, Palvella and Bridgebio in February - bioworld.com

Mar 27, 2026

Mar 26, 2026

Vanguard disaggregates holdings; reports 0 Bridgebio shares (BBIO) - Stock Titan

Mar 26, 2026

Returns Recap: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEAR - baoquankhu1.vn

Mar 26, 2026

Mar 25, 2026

Market Catalysts: Whats next for BridgeBio Pharma Inc stock2026 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

1BBIO.MI Stock Price, Quote & Chart | BRIDGEBIO PHARMA INC (BIT:1BBIO) - chartmill.com

Mar 24, 2026

Mar 23, 2026

MOODY ALDRICH PARTNERS LLC's BridgeBio Pharma Inc(BBIO) Holding History - GuruFocus

Mar 23, 2026

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions - The Manila Times

Mar 23, 2026

BridgeBio heart drug lands late-breaking ACC slot with survival data - stocktitan.net

Mar 23, 2026

Mar 22, 2026

Aug Retail: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARPortfolio Profit Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn

Mar 22, 2026

Mar 20, 2026